Tags

Type your tag names separated by a space and hit enter

Rediscovery of insulin pump treatment of childhood type 1 diabetes.
Minerva Med. 2004 Apr; 95(2):85-92.MM

Abstract

Currently, goals for the treatment of children and adolescents with type 1 diabetes mellitus are to achieve near normal glycemia; minimize the risks of severe hypoglycemia and excessive weight gain; optimize psychosocial functioning and quality of life (for children and their families); and prevent or delay long-term microvascular complications. Continuous subcutaneous insulin infusion (CSII), or insulin pump therapy, provides a treatment option that can assist in the attainment of all of these goals in all ages of children. Insulin pump therapy provides the opportunity for greater flexibility in meal timing and content due to the convenience of its bolus delivery of insulin. Insulin pump therapy can potentially reduce the risk of exercise-related and nocturnal hypoglycemia, through the use of programmable variable basal infusion rates. In pediatric patients, usage of CSII has been demonstrated to reduce both glycosylated hemoglobin levels and frequency of severe hypoglycemia, without sacrifices in safety, quality of life, or weight gain, particularly in conjunction with the use of new insulin analogs and improvements in pump technology. Clinical studies of safety and efficacy of CSII in children and the use of continuous glucose monitoring to optimize insulin pump therapy are reviewed.

Authors+Show Affiliations

Weinzimer SA
Clinical Department of Pediatrics and the Children's Research Center, Yale University School of Medicine New Haven, CT 06520, USA.
Doyle EA
No affiliation info available
Steffen AT
No affiliation info available
Sikes KA
No affiliation info available
Tamborlane WV
No affiliation info available

MeSH

Blood Glucose Self-MonitoringChildClinical Trials as TopicDiabetes Mellitus, Type 1HumansHypoglycemic AgentsInsulinInsulin Infusion Systems

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Review

Language

eng

PubMed ID

15272243

Citation

Weinzimer, S A., et al. "Rediscovery of Insulin Pump Treatment of Childhood Type 1 Diabetes." Minerva Medica, vol. 95, no. 2, 2004, pp. 85-92.
Weinzimer SA, Doyle EA, Steffen AT, et al. Rediscovery of insulin pump treatment of childhood type 1 diabetes. Minerva Med. 2004;95(2):85-92.
Weinzimer, S. A., Doyle, E. A., Steffen, A. T., Sikes, K. A., & Tamborlane, W. V. (2004). Rediscovery of insulin pump treatment of childhood type 1 diabetes. Minerva Medica, 95(2), 85-92.
Weinzimer SA, et al. Rediscovery of Insulin Pump Treatment of Childhood Type 1 Diabetes. Minerva Med. 2004;95(2):85-92. PubMed PMID: 15272243.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Rediscovery of insulin pump treatment of childhood type 1 diabetes. AU - Weinzimer,S A, AU - Doyle,E A, AU - Steffen,A T, AU - Sikes,K A, AU - Tamborlane,W V, PY - 2004/7/24/pubmed PY - 2004/7/30/medline PY - 2004/7/24/entrez SP - 85 EP - 92 JF - Minerva medica JO - Minerva Med VL - 95 IS - 2 N2 - Currently, goals for the treatment of children and adolescents with type 1 diabetes mellitus are to achieve near normal glycemia; minimize the risks of severe hypoglycemia and excessive weight gain; optimize psychosocial functioning and quality of life (for children and their families); and prevent or delay long-term microvascular complications. Continuous subcutaneous insulin infusion (CSII), or insulin pump therapy, provides a treatment option that can assist in the attainment of all of these goals in all ages of children. Insulin pump therapy provides the opportunity for greater flexibility in meal timing and content due to the convenience of its bolus delivery of insulin. Insulin pump therapy can potentially reduce the risk of exercise-related and nocturnal hypoglycemia, through the use of programmable variable basal infusion rates. In pediatric patients, usage of CSII has been demonstrated to reduce both glycosylated hemoglobin levels and frequency of severe hypoglycemia, without sacrifices in safety, quality of life, or weight gain, particularly in conjunction with the use of new insulin analogs and improvements in pump technology. Clinical studies of safety and efficacy of CSII in children and the use of continuous glucose monitoring to optimize insulin pump therapy are reviewed. SN - 0026-4806 UR - https://www.unboundmedicine.com/medline/citation/15272243/Rediscovery_of_insulin_pump_treatment_of_childhood_type_1_diabetes_ DB - PRIME DP - Unbound Medicine ER -